Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment ...

Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year ...

Then: In a 2021 “Companies To Watch” article written by Wayne Koberstein, Carisma Therapeutics CEO Steven Kelly spoke about his three-pronged mandate to fund the (then) privately held company, build a ...

Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market ...

Single-use (SU) systems show significant promise for antibody-drug conjugate (ADC) manufacturing. However, the use of organic solvents in the ADC process raises concerns about potential leachables ...

Melissa Leichter, a Novo Nordisk executive, describes the distinct skills and mindset needed to succeed in bringing rare disease treatments to market.

Over the past decade, advances in drug discovery and clinical development have led to a rise in the number of approved therapies, resulting in an increasingly competitive marketplace. These evolving ...